This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Mark Dennis, PhD
Fellow at Denali Therapeutics


Building on 35 years of experience in protein and antibody
engineering while a Principal Scientist at Genentech, Mark is
currently a Fellow at Denali Therapeutics providing strategic
direction and guidance for the development of protein
therapeutics targeting neurological diseases. While at
Genentech, Mark developed a practical method to deliver
biotherapeutics across the blood-brain barrier, established that
association with albumin could increase the serum half-life of
biotherapeutics and was a key member of teams establishing
early Antibody-drug conjugate (ADC) and T-cell Dependent
Bispecific (TDC) technologies for oncology. Mark has
authored over 60 papers and contributed to over 30 granted